| Added by | ircm doc |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort |
| Creator | Galvin et al. |
| Author | Angéline Galvin |
| Author | Coralie Courtinard |
| Author | Fanny Bouteiller |
| Author | Sophie Gourgou |
| Author | Florence Dalenc |
| Author | William Jacot |
| Author | Monica Arnedos |
| Author | Caroline Bailleux |
| Author | Véronique Dieras |
| Author | Thierry Petit |
| Author | George Emile |
| Author | Pascale Dubray-Longeras |
| Author | Jean-Sébastien Frenel |
| Author | Thomas Bachelot |
| Author | Audrey Mailliez |
| Author | Etienne Brain |
| Author | Isabelle Desmoulins |
| Author | Vincent Massard |
| Author | Anne Patsouris |
| Author | Anthony Goncalves |
| Author | Thomas Grinda |
| Author | Suzette Delaloge |
| Author | Carine Bellera |
| Abstract | AIM: To describe first-line treatment patterns, overall survival (OS) and real-world progression-free survival (rwPFS) in young women (<40) with metastatic breast cancer (mBC), as compared to women aged 40-69. MATERIALS AND METHODS: Data on adult women diagnosed with mBC (2008-2017) were extracted from the ESME mBC database (NCT03275311) which includes consecutive patients starting first-line metastatic treatment in one of the 18 French Comprehensive cancer centers. We reported first-line therapeutic strategy and prognostic factors of OS and rwPFS for women aged < 40 and 40-69. RESULTS: In total, 14,897 mBC women were included (1512 aged <40). HR+ /HER2- mBC was the most frequent subtype. First-line treatment differed between young patients and older ones for HR+ /HER2- and Triple Negative (TN) mBC. Median OS for women aged < 40 and 40-69, respectively, was 46.9 and 46.2 months for HR+ /HER2- mBC; 13.5 and 15.2 for TN mBC; and, 60.7 and 55.1 for HER2 + mBC. Median rwPFS under first line treatment was 11.6 and 11.9 months for HR+ /HER2- in women aged < 40 and 40-69, respectively; 5.5 and 5.9 for TN, and, 13.3 and 12.9 for HER2 + . Factors associated with shorter OS and rwPFS were similar for both women aged < 40 and 40-69 and included ? 3 metastatic sites, visceral metastases, and longer MFI, with time-varying effects observed for several prognostic factors. CONCLUSION: Young women presented more frequently with TN and HER2 + subtypes and aggressive mBC than women aged 40-69 did. Prognostic factors of OS and rwPFS were quite similar between age groups and mBC subtypes. |
| Publication | European Journal of Cancer (Oxford, England: 1990) |
| Volume | 196 |
| Pages | 113422 |
| Date | 2024-01 |
| Journal Abbr | Eur J Cancer |
| Language | eng |
| DOI | 10.1016/j.ejca.2023.113422 |
| ISSN | 1879-0852 |
| Library Catalog | PubMed |
| Extra | PMID: 37977105 |
| Tags | Adult, Aged, Breast Neoplasms, clinic, Databases, Factual, Female, Humans, Middle Aged, Progression-Free Survival, Real-word data, Receptor, ErbB-2, Retrospective Studies, Survival endpoints, Triple Negative Breast Neoplasms |
| Date Added | 2025/01/13 - 11:59:44 |
| Date Modified | 2025/01/16 - 09:48:56 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
